MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 76 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $935,418 | +31.5% | 116,201 | +77.3% | 0.00% | – |
| Q2 2023 | $711,580 | -33.1% | 65,523 | -57.5% | 0.00% | – |
| Q1 2023 | $1,063,697 | +58.9% | 154,159 | -8.3% | 0.00% | – |
| Q4 2022 | $669,321 | -55.7% | 168,171 | -26.0% | 0.00% | – |
| Q3 2022 | $1,511,000 | +586.8% | 227,219 | +398.5% | 0.00% | – |
| Q2 2022 | $220,000 | -85.0% | 45,584 | -71.0% | 0.00% | – |
| Q1 2022 | $1,468,000 | -18.4% | 156,949 | +3.5% | 0.00% | – |
| Q4 2021 | $1,800,000 | -33.8% | 151,569 | -36.6% | 0.00% | -100.0% |
| Q3 2021 | $2,721,000 | -35.4% | 239,125 | +1.8% | 0.00% | 0.0% |
| Q2 2021 | $4,214,000 | +18.3% | 234,872 | +2.1% | 0.00% | 0.0% |
| Q1 2021 | $3,561,000 | +363.7% | 229,994 | +265.2% | 0.00% | – |
| Q4 2020 | $768,000 | +88.2% | 62,976 | +98.5% | 0.00% | – |
| Q3 2020 | $408,000 | – | 31,723 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |